90392963 - GALENAGEN

Information

• Trademark
• 90392963

• Source

• Serial Number

  90392963

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  December 18, 2020
  3 years ago

• Transaction Date

  April 03, 2024
  5 months ago

• Status Date

  April 02, 2024
  5 months ago

• Published for Opposition Date

  August 10, 2021
  3 years ago

• Location Date

  October 05, 2021
  2 years ago

• Status Code

  734

• Current Location

  INTENT TO USE SECTION

  Employee Name

  MASULLO, MARCO

• Attorney Docket Number

  U2400-00072

  Attorney Name

  Nicole K. McLaughlin

  Law Office Assigned Location Code

  N50

• Owners

  • GALENAGEN, LLC

Case File Statements

• GS0051: Pharmaceutical preparations and substances for the diagnosis, treatment and prevention of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; Antibacterial, antiviral and antifungal preparations for skin and wound healing; disinfectants and antiseptics; antimicrobial cleansers for sanitation purposes; Medical assays for testing of bodily fluids and tissues for testing of enzymes in humans; biological preparations for medical testing; diagnostic preparations for medical purposes; testing kits comprised of medical diagnostic reagents and assays for testing enzymes and body fluids for use in disease detection; medical diagnostic reagents and assays for testing of enzymes and body fluids; chemical preparations for medical testing; diagnostic biomarker reagents for medical testing; all the foregoing for the diagnosis and treatment of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders
• GS0441: Medical testing for diagnostic and treatment purposes; Medical consultations; medical testing for diagnostic treatment purposes in the fields of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; medical testing for diagnostic treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; Medical diagnostic testing, monitoring and reporting services; performing diagnosis of diseases; Health care services, namely, the administration of medical assays for the detection of enzymes in humans
• GS0421: Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical research; Development of pharmaceuticals and medical devices for others; Providing temporary use of non-downloadable computer software that allows users to make determinations regarding neurological diseases, specifically baseline staging, data gathering and monitoring of early, middle and late stage neurological diseases; Design and development of medical assays for others; clinical research and development of treatments for viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; clinical research and development of treatments for the treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; clinical research and development of treatments for antibacterial, antiviral, and antifungal preparations for skin and wound healing; clinical research and development of disinfectants, antiseptics and antimicrobial cleansers for sanitation purposes; medical and scientific research services in the field of digestion and detection of enzymes or biological substances in the body

Case File Event Statements

• 4/3/2024 - 5 months ago

  28 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 4/2/2024 - 5 months ago

  27 - SOU EXTENSION 5 GRANTED Type: EX5G

• 4/2/2024 - 5 months ago

  26 - SOU EXTENSION 5 FILED Type: EXT5

• 4/2/2024 - 5 months ago

  25 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 10/4/2023 - 11 months ago

  24 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 10/2/2023 - 11 months ago

  23 - SOU EXTENSION 4 GRANTED Type: EX4G

• 10/2/2023 - 11 months ago

  22 - SOU EXTENSION 4 FILED Type: EXT4

• 10/2/2023 - 11 months ago

  21 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 3/31/2023 - a year ago

  20 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 3/29/2023 - a year ago

  19 - SOU EXTENSION 3 GRANTED Type: EX3G

• 3/29/2023 - a year ago

  18 - SOU EXTENSION 3 FILED Type: EXT3

• 3/29/2023 - a year ago

  17 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 10/4/2022 - a year ago

  16 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 9/30/2022 - a year ago

  15 - SOU EXTENSION 2 GRANTED Type: EX2G

• 9/30/2022 - a year ago

  14 - SOU EXTENSION 2 FILED Type: EXT2

• 9/30/2022 - a year ago

  13 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 3/30/2022 - 2 years ago

  12 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 3/28/2022 - 2 years ago

  11 - SOU EXTENSION 1 GRANTED Type: EX1G

• 3/28/2022 - 2 years ago

  10 - SOU EXTENSION 1 FILED Type: EXT1

• 3/28/2022 - 2 years ago

  9 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 10/5/2021 - 2 years ago

  8 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 8/10/2021 - 3 years ago

  7 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 8/10/2021 - 3 years ago

  6 - PUBLISHED FOR OPPOSITION Type: PUBO

• 7/21/2021 - 3 years ago

  5 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 7/8/2021 - 3 years ago

  4 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 6/14/2021 - 3 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 3/1/2021 - 3 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 12/22/2020 - 3 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP